Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Leukemia, Myeloid, Acute trials
The registry lists 13 Leukemia, Myeloid, Acute studies with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor. 1 are open to participants now and 5 have results posted.
Early Phase 1 1Phase 1 5Phase 2 5Phase 3 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
- Post-transplant Flotetuzumab for AMLCompletedNCT05506956Phase 1Results posted
- Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older PatientsCompletedNCT02845297Phase 2Results posted
- Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDSCompletedNCT01700673Phase 2Results posted
- Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell BehaviorTerminatedNCT01588951Phase 2/3Results posted
- Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic CancersTerminatedNCT01135329Phase 2Results posted
- Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AMLTerminatedNCT05716009Phase 1
- Resiliency in Older Adults Undergoing Bone Marrow TransplantCompletedNCT04188678
- Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeTerminatedNCT02749708Phase 1
- Red Cell Transfusion Goals in Patients With Acute LeukemiasCompletedNCT02086773Phase 1
- Studying Fentanyl in Patients With CancerTerminatedNCT00899951
- Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00004871Phase 1
- Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous LeukemiaCompletedNCT00003340Phase 2